Risultati di ricerca
1 giorno fa · Contributo: Carola Buscemi Semaglutide versus placebo nello scompenso cardiaco correlato a obesità, con frazione di eiezione preservata: analisi aggregata degli studi STEP-HFpEF e STEP-HFpEF DM Abstract Introduzione Negli studi STEP-HFpEF (NCT04788511) e STEP-HFpEF DM (NCT04916470), l’agonista recettoriale del recettore del GLP-1, semaglutide, ha dimostrato di migliorare i sintomi, ridurre ...
3 giorni fa · Placebo a Rock in Roma 2024. Dove Ippodromo Capannelle. Via Appia Nuova, 1245. Quando Dal 08/07/2024 al 08/07/2024 Apertura porte: h 19:00 Inizio concerto: h 21:45. Prezzo Prezzo non disponibile ...
12 ore fa · Please note that the individuals shown in this video are for illustrative purposes only. Thank you for watching.The placebo effect is a fascinating phenomeno...
- 2 min
- Gigihub
2 giorni fa · ESC Heart Failure 2024 - In a prespecified analysis of SELECT among CVD patients with BMI ≥27 kg/m², the efficacy and safety of semaglutide versus placebo on the rates of MACE, HF-related events, and all-cause mortality were not influenced by history of HF or HF subtype. This summary is based on the presentation of John Deanfield, MD (London ...
2 giorni fa · GSK plc (LSE/NYSE: GSK) today announced positive headline results from the phase III clinical trials SWIFT-1 and SWIFT-2, which assessed the efficacy and safety of depemokimab versus placebo in adults and adolescents with severe asthma with type 2 inflammation characterised by blood eosinophil count.1,2 Both SWIFT-1 and SWIFT-2 met their ...
3 giorni fa · This randomised, double-blind, placebo-controlled, phase 2 study was conducted at 26 hospitals in China. Eligible patients were aged 18–70 years, had primary immune thrombocytopenia for more than 6 months, and did not respond or relapsed after previous treatment and had a pre-treatment platelet count of <30 × 10 9 /L. Patients randomly received zuberitamab in a dose escalation (100/300/600 ...
1 giorno fa · Participants with clinical knee osteoarthritis, significant knee pain, and effusion-synovitis on magnetic resonance imaging were enrolled from December 2016 to June 2019; final follow-up occurred on February 7, 2020. InterventionsParticipants were randomized to 2 g/d of krill oil (n = 130) or matching placebo (n = 132) for 24 weeks.
